Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
December 09 2020 - 4:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
December 2020
Commission file number: 001-36288
Akari Therapeutics, Plc
(Translation of registrant's name into English)
75/76 Wimpole Street
London W1G 9RT
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form
40-F ¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):
CONTENTS
On December 9, 2020,
Akari Therapeutics, Plc (the “Company”) announced that all resolutions put to shareholders
at its General Meeting of Shareholders held on December 8, 2020 were passed.
As a result of the
General Meeting of Shareholders, the currency of the Company’s ordinary shares will be changed from pounds sterling to US
dollars and the nominal (par) value of an ordinary share will be reduced to USD0.0001.
Following the completion
of the foregoing, the number of ordinary shares in issue will be the same as immediately before the changes and each shareholder’s
proportionate interest in the Company will remain unchanged. The only change will be to the nominal value of a share. The rights
attaching to the ordinary shares of USD0.0001 (including voting, dividend and capital rights) will be unchanged and there will
also be no direct effect on the value of the Company’s ADSs.
The information contained
in this report (including the exhibits hereto) is hereby incorporated by reference into all effective registration statements filed
by the Company under the Securities Act of 1933.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
Akari Therapeutics, Plc
|
|
(Registrant)
|
|
|
|
|
|
|
|
By:
|
/s/ Clive Richardson
|
|
Name:
|
Clive Richardson
|
|
|
Chief Executive Officer and Chief Operating Officer
|
Date: December 9, 2020
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Sep 2023 to Sep 2024